Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Non-randomized, Single-arm, Open-label Study to Assess the Immunogenicity, Safety and Reactogenicity of Combined Reduced-antigen-content Diphtheria, Tetanus and Acellular Pertussis (dTpa) Vaccine, Administered as a Booster Dose in Healthy Japanese Adolescents Aged 11 Years to <13 Years

NCT07596173 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT07596173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07596173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Non-randomized, Single-arm, Open-label Study to Assess the Immunogenicity, Safety and Reactogenicity of Combined Reduced-antigen-content Diphtheria, Tetanus and Acellular Pertussis (dTpa) Vaccine, Administered as a Booster Dose in Healthy Japanese Adolescents Aged 11 Years to <13 Years
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
June 29, 2026
Completion date
September 4, 2026
Enrollment
90 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

diphtheria-tetanus-acellular pertussis vaccines